WO2007039754A1 - Use of oligouronates for treating mucus hyperviscosity - Google Patents

Use of oligouronates for treating mucus hyperviscosity Download PDF

Info

Publication number
WO2007039754A1
WO2007039754A1 PCT/GB2006/003720 GB2006003720W WO2007039754A1 WO 2007039754 A1 WO2007039754 A1 WO 2007039754A1 GB 2006003720 W GB2006003720 W GB 2006003720W WO 2007039754 A1 WO2007039754 A1 WO 2007039754A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligouronate
treatment
physiologically tolerable
mucus
mucosal
Prior art date
Application number
PCT/GB2006/003720
Other languages
French (fr)
Inventor
Catherine Taylor
Kurt Ingar Draget
Olav Asmund Smidsrod
Original Assignee
Ntnu Technology Transfer As
Cockbain, Julian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35429950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007039754(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0616982A priority Critical patent/BRPI0616982B8/en
Priority to EP06794671A priority patent/EP1942938B1/en
Priority to KR1020087010474A priority patent/KR101144576B1/en
Priority to AU2006298544A priority patent/AU2006298544B2/en
Priority to DK06794671.5T priority patent/DK1942938T3/en
Application filed by Ntnu Technology Transfer As, Cockbain, Julian filed Critical Ntnu Technology Transfer As
Priority to ES06794671T priority patent/ES2390974T3/en
Priority to JP2008534075A priority patent/JP5313677B2/en
Priority to US12/089,529 priority patent/US8754063B2/en
Priority to CN2006800460615A priority patent/CN101325973B/en
Priority to EA200801033A priority patent/EA015436B1/en
Priority to CA2624568A priority patent/CA2624568C/en
Publication of WO2007039754A1 publication Critical patent/WO2007039754A1/en
Priority to HK09104636.3A priority patent/HK1125855A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Definitions

  • This invention relates to a method of treatment of human or non-human animals, in particular mammals, with oligouronates to combat elevated mucosal viscosity, e.g. to enhance mucus clearance, especially from the respiratory tract such as in the case of COPD 's (chronic obstructive pulmonary diseases) , in particular the sinuses and the lungs, in particular in the treatment of cystic fibrosis (CF) , chronic obstructive pulmonary disease and sinusitis.
  • COPD 's chronic obstructive pulmonary diseases
  • CF cystic fibrosis
  • Cystic fibrosis is the most common lethal genetic disease in European populations .
  • the disease is caused by a mutation in the gene that codes for the cystic fibrosis transmembrane regulator (CFTR) , a chloride channel that is present in secretary and other cells in the body.
  • CFTR cystic fibrosis transmembrane regulator
  • the disease is characterized by the presence of thick, intractable mucus secretions in the body that can lead to lung disease, digestive problems and infertility.
  • the normal pattern of mucociliary clearance in the lungs fails to clear the unduly viscous mucus which becomes colonized by microorganisms, which in turn increases mucus viscosity and may lead to chronic lung inflammation and obstruction. Lung disease is thus the biggest health problem for the majority of CF patients and is the major cause of death.
  • Mucus is a normal secretion of the entire respiratory tract, including the lungs. Its primary function is as part of the mucociliary clearance system that keeps the lungs clean and protects against infection.
  • the mucociliary clearance system has three main components: mucus; cilia; and the airway surface liquid.
  • the epithelial surface thus comprises mucus secreting goblet cells and ciliated epithelial cells with an overlying layer of airway surface liquid and above that a layer of mucus, into which the tips of the cilia protrude.
  • the mucus is a sticky gel material composed primarily of water (about 95% wt.) and mucins, gel forming molecules responsible for the physical properties of the mucus.
  • the cilia are small hair-like projections from the surface of the epithelial cells, which beat rhythmically in the watery, non-viscous airway surface liquid with their tips immersed in the mucus layer.
  • the mucus layer forms a sticky blanket on the lung surface that traps bacteria, viruses, inhaled particles, environmental pollutants and cell debris .
  • the beating of the cilia serves to propel this mucus blanket and anything trapped in it towards the mouth and out of the lungs .
  • the mucociliary clearance system functions effectively and the lungs are kept clean and free of infection. If the system is overwhelmed, there is a second line of defence - cough.
  • the mucus is projected out of the lungs by the cough reflex.
  • the mucus in the lung is thicker and more viscous than normal, and this thicker mucus is not so easily transported by the cilia. As a result the mucociliary clearance system is compromised and the lungs are more vulnerable to infection.
  • the lungs of CF patients appear to be in a hyper- inflammatory state with a continual low level of inflammation and a heightened response to agents that normally cause inflammation. This is problematic as part of the response to inflammation is increased production of mucus. The increased mucus builds up if it is too thick to be cleared by the mucociliary clearance system or coughing, lung capacity is reduced and the exchange of oxygen across the mucosa is decreased.
  • oligouronates i.e. multiply charged hydroxyl group carrying oligomers, in particular one containing two to thirty monomer residues .
  • the invention provides a method of treatment of a human or non-human (e.g. mammalian) subject to combat mucosal hyperviscosity in the respiratory tract, e.g. to treat chronic obstructive pulmonary disease, sinusitis or cystic fibrosis patients, which method comprises application to a mucosal surface in said tract in said subject of an effective amount of a physiologically tolerable oligouronate polyol.
  • a human or non-human (e.g. mammalian) subject to combat mucosal hyperviscosity in the respiratory tract, e.g. to treat chronic obstructive pulmonary disease, sinusitis or cystic fibrosis patients, which method comprises application to a mucosal surface in said tract in said subject of an effective amount of a physiologically tolerable oligouronate polyol.
  • the invention provides the use of a physiologically tolerable oligouronate for the manufacture of a medicament for use in the treatment of ⁇ mucosal hyperviscosity in the respiratory tract.
  • the application of the oligouronate may be by any means which delivers it to a mucus secreting, or mucus carrying surface in the patient's respiratory tract, e.g. the paranasal sinuses or more preferably the lungs.
  • Introduction will typically be by inhalation, e.g. of liquid ⁇ droplets (for example an aerosol) or a powder.
  • the counterions for the oligouronate may be any of the physiologically tolerable ions commonly used for charged drug substances, e.g. sodium, potassium, ammonium, chloride, mesylate, meglumine, etc. Ions which promote alginate gelation, e.g. group 2 metals, however will preferably not be used.
  • the oligouronate may be a synthetic material, it is preferably a derivative, having a weight average molecular weight of less than 100000 Da, of a naturally occurring polysaccharide. It is preferably a 3- to 28- mer, in particular a 4- to 25-mer, especially a 6- to 22-mer, in particular an 8- to 15-mer, especially a 10- mer, e.g. having a molecular weight in the range 350 to 6000 Da especially 750 to 4500 Da. It may be a single compound or it may be a mixture of oligouronate compounds, e.g. of a range of degrees of polymerization. Moreover, the monomeric residues in the oligouronate, e.g.
  • the monosaccharide groups may be the same or different and not all need carry electrically charged groups although it is preferred that the majority (e.g. at least 60%, preferably at least 80% more preferably at least 90%) do. It is preferred that a substantial majority, e.g. at least 80%, more preferably at least 90% of the charged groups have the same polarity.
  • the ratio of hydroxyl groups to charged groups is preferably at least 2:1, more especially at least 3:1.
  • Oligouronates are readily accessible from natural sources since many natural polysaccharides contain charged uronate residues, e.g. residues such as guluronic and galacturonic acid residues.
  • Polysaccharide to oligosaccharide cleavage to produce oligosuronate useable according to the present invention may be performed using conventional polysaccharide lysis techniques such as enzymatic digestion and acid hydrolysis . Oligouronates may then be separated from the polysaccharide breakdown products chromatographycalIy using an ion exchange resin or by fractionated precipitation or solubilization.
  • the oligouronates may also be chemically modified, including but not limited to modification to add charged groups (such as carboxylated or carboxymethylated glycans), and oligouronates modified to alter flexibility (e.g. by periodate oxidation)
  • Suitable polysaccharides are discussed for example in "Handbook of Hydrocolloids” , Ed. Phillips and Williams, CRC, Boca Raton, Florida, USA, 2000.
  • the use of alginates however is especially preferred as these naturally occur as block copolymers of manuronic (M) and guluronic (G) acids and G-block oligomers can readily be produced from alginate source materials .
  • the oligouronate is preferably an oligoguluronic acid, or less preferably an oligogalacturonic acid.
  • the guluronic acid content may if desired be increased by epimerization with mannouronan C-5 epimerases from A. vinelandii .
  • Oligoguluronic acids suitable for use according to the invention may conveniently be produced by acid hydrolysis of alginic acid from Laminaria hyperborea, dissolution at neutral pH, addition of mineral acid to reduce the pH to 3.4 to precipitate the oligoguluronic acid, washing with weak acid, resuspension at neutral pH and freeze drying.
  • the invention also provides a pharmaceutical composition, especially an inhalable composition, e.g. a solution, suspension, dispersion or powder, comprising a physiologically tolerable oligouronate together with a physiologically tolerable carrier or excipient, and preferably also a further physiologically tolerable mucosal viscosity reducing agent, e.g. a nucleic acid cleaving enzyme (e.g. a DNAse such as DNase I) , gelsolin, a thiol reducing agent, an acetylcysteine, sodium chloride, an uncharged low molecular weight polysaccharide (e.g.
  • a nucleic acid cleaving enzyme e.g. a DNAse such as DNase I
  • gelsolin e.g. a thiol reducing agent
  • an acetylcysteine sodium chloride
  • an uncharged low molecular weight polysaccharide e.g.
  • the oligouronate may be administered typically in doses of 1 to lOOOOmg, especially 10 to lOOOmg for an adult human. The optimum does may readily be determined by routine dosage ranging experiments, optionally following initial investigation of an animal model, e.g. a dog model.
  • compositions of the invention may be produced using conventional pharmaceutical carriers and excipients, e.g. solvents (such as water), osmolality modifiers, flavours, pH regulators, etc. They may contain additional active components, for example agents which serve to break down biopolymers not involved in the mucin matrix of the mucus (e.g. DNase, particularly rhDNase) , antibacterial agents, and antiinflammatories. Combination therapy using a such further agent and the oligouronate, administered separately or together is a particularly preferred aspect of the method of the invention. Such further agents may be used in their normal doses or even at lower doses, e.g. 50% of normal dose.
  • solvents such as water
  • osmolality modifiers such as water
  • flavours such as water
  • pH regulators e.g., etc.
  • additional active components for example agents which serve to break down biopolymers not involved in the mucin matrix of the mucus (e.g. DNase, particularly rhDNase)
  • the oligouronates are desirably administered as a spray, preferably an aerosol spray made from an aqueous solution or in the form of powders, e.g. of approximately nanometer to micrometer (e.g. 10 to 50000 nm) mode particle size by volume size.
  • the invention provides a spray applicator comprising a reservoir and a droplet generator, said reservoir containing an aqueous solution of a physiologically tolerable oligouronate.
  • a spray applicator comprising a reservoir and a droplet generator, said reservoir containing an aqueous solution of a physiologically tolerable oligouronate.
  • Such spray applicators, and indeed the oligouroantes may be used in the treatment of sinus or nasal blockage or congestion resulting from the common cold or other reasons .
  • Figures Ia to If are plots of complex modulus over time for a mucin-alginate gel and for the same gel dosed with dextran, polyethylene glycol, DNA, sodium galacturonate oligomer and sodium guluronate oligomer respectively;
  • Figures 2 and 3 are bar charts showing the complex modulus (G*) and the phase angle of the same gels at the end of gelation as a percentage of the control;
  • Figure 4 is a bar chart showing the flow stress of the same gels, again as a percentage of the control
  • Figures 5a and 5b show the complex modulus G* for treated and untreated sputum samples from CF patients, Figure 5b showing G* as a percentage of control (the untreated sputum) ; Figures 5c to 5f show plots of G* over time;
  • Figures 6a and 6b show the complex viscosity ( ⁇ *) for treated and untreated sputum samples, Figure 6b showing ⁇ * as a percentage of control;
  • Figures 7a and 7b show the phase angle ⁇ for treated and untreated sputum samples .
  • Figure 7b showing ⁇ as a percentage of control.
  • Control gel consisted of 18mg/ml mucin + 0.6mg/ml alginate in 0.05M NaCl
  • Test gels consisted of 18mg/ml mucin + 0.6mg/ml alginate + 4mg/ml test material in 0.05 M NaCl
  • the complex modulus and phase angle of the gels at the end of the gelling period is plotted in Figures 2 and 3.
  • the complex modulus is a measure of the total response or strength of the system and the phase angle concerns the balance between liquid like and solid like behaviour with a higher phase angle indicating greater liquid like behaviour.
  • Sodium guluronate oligomers (G blocks) caused the greatest drop in G* and the greatest increase in the phase angle.
  • a stress sweep was used to determine the stress needed to induce flow in the system. This is plotted in Figure 4 as a % of the stress needed to induce flow in the control gel. This gives an indication of how much the added material has weakened the gel matrix. G blocks (sodium guluronate oligomers) had the most pronounced effect on the flow stress followed by sodium galacturonate oligomers .
  • Sputum samples were collected from cystic fibrosis patients with a positive diagnosis for Pseudomonas aeruginosa infection. The samples were gently stirred, divided into portions, frozen and stored at -40 0 C.
  • the sputum samples were taken out from the freezer and placed in the fridge (4°C) one hour before testing, stirred on a magnetic stirrer for about 10 min and divided into 0.5 g portions. Testing media was added to all but one sample, the pure sputum sample. The resulting samples were:
  • the mixed samples were then gently stirred for 1 min and subsequently placed into the fridge for 5 min before being transferred to the rheometer for testing.
  • Figure 5a is bar chart showing the complex modulus (G*) for the sputum samples at the end of testing, after 60 min.
  • Figure 5b is bar chart showing the same sputum samples as in figure 5a, but as percentage of the control (pure sputum) .
  • Figure 5c to 5f are plots of complex modulus over time for the sputum samples A to D.
  • Figure 6a is bar chart showing the complex viscosity ( ⁇ *) for the sputum samples at the end of testing, after 60 min.
  • Figure 6b is bar chart showing the same sputum samples as in figure 6a, but as percentage of the control .
  • Figure 7a is bar chart showing the phase angle ( ⁇ ) for the sputum samples at the end of testing, after 60 min.
  • Figure 7b is bar chart showing the same sputum samples as in figure 3a, but as percentage of the control.
  • a sterile aerosol spray administered by the aid of a nebuliser, is made from a liquid containing 3-10% of the sodium salt of a guluronic acid block with a purity of at least 75% guluronate and a degree of polymerisation between 5 and 20, and, if necessary, a surface active compound to stabilise the aerosol droplet size.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a method of treatment of a human or non-human subject to combat mucosal hyperviscosity in the respiratory tract, which method comprises application to a mucosal surface in said tract in said subject of an effective amount of a physiologically tolerable oligouronate.

Description

Oligouronate Treatment
This invention relates to a method of treatment of human or non-human animals, in particular mammals, with oligouronates to combat elevated mucosal viscosity, e.g. to enhance mucus clearance, especially from the respiratory tract such as in the case of COPD 's (chronic obstructive pulmonary diseases) , in particular the sinuses and the lungs, in particular in the treatment of cystic fibrosis (CF) , chronic obstructive pulmonary disease and sinusitis.
Cystic fibrosis is the most common lethal genetic disease in European populations . The disease is caused by a mutation in the gene that codes for the cystic fibrosis transmembrane regulator (CFTR) , a chloride channel that is present in secretary and other cells in the body. The disease is characterized by the presence of thick, intractable mucus secretions in the body that can lead to lung disease, digestive problems and infertility. The normal pattern of mucociliary clearance in the lungs fails to clear the unduly viscous mucus which becomes colonized by microorganisms, which in turn increases mucus viscosity and may lead to chronic lung inflammation and obstruction. Lung disease is thus the biggest health problem for the majority of CF patients and is the major cause of death.
Mucus is a normal secretion of the entire respiratory tract, including the lungs. Its primary function is as part of the mucociliary clearance system that keeps the lungs clean and protects against infection. The mucociliary clearance system has three main components: mucus; cilia; and the airway surface liquid. The epithelial surface thus comprises mucus secreting goblet cells and ciliated epithelial cells with an overlying layer of airway surface liquid and above that a layer of mucus, into which the tips of the cilia protrude. The mucus is a sticky gel material composed primarily of water (about 95% wt.) and mucins, gel forming molecules responsible for the physical properties of the mucus. The cilia are small hair-like projections from the surface of the epithelial cells, which beat rhythmically in the watery, non-viscous airway surface liquid with their tips immersed in the mucus layer. The mucus layer forms a sticky blanket on the lung surface that traps bacteria, viruses, inhaled particles, environmental pollutants and cell debris . The beating of the cilia serves to propel this mucus blanket and anything trapped in it towards the mouth and out of the lungs . Under normal conditions, the mucociliary clearance system functions effectively and the lungs are kept clean and free of infection. If the system is overwhelmed, there is a second line of defence - cough. Thus when increased levels of mucus are secreted in response to irritation or inflammation, e.g. due to inhaled particles or infection, the mucus is projected out of the lungs by the cough reflex.
In CP patients the mucus in the lung is thicker and more viscous than normal, and this thicker mucus is not so easily transported by the cilia. As a result the mucociliary clearance system is compromised and the lungs are more vulnerable to infection. In addition, the lungs of CF patients appear to be in a hyper- inflammatory state with a continual low level of inflammation and a heightened response to agents that normally cause inflammation. This is problematic as part of the response to inflammation is increased production of mucus. The increased mucus builds up if it is too thick to be cleared by the mucociliary clearance system or coughing, lung capacity is reduced and the exchange of oxygen across the mucosa is decreased. This provides an ideal environment for bacterial colonisation, a serious problem for CF patients as it also causes inflammation and activates the immune response. This leads not only to increased mucus secretion but also an increased presence of immune response cells and agents such as macrophages and lysozymes . As bacteria and macrophages die, their cell contents are released into the mucus and these include viscous molecules such as DNA. Furthermore, some of the bacteria, e.g. Burkholderia sp. and Pseudomonas aeruginosa, also secrete highly viscous polysaccharides, in the latter case alginates . These molecules further increase the viscosity of the mucus, in the case of the alginates apparently by interaction with the mucin matrix of the mucus but in the case of DNA apparently by increasing the viscosity of the sol phase within the mucin matrix.
Maintaining the mucus in a form capable of being transported by the cilia is thus a key goal of treatment of CF. Agents which simply break down its gel-like structure would result in fluid which was as untransportable as the hyperviscous mucus of the CF patient. It is important therefore that any treatment agent should not break down the gel matrix formed by the glycoprotein mucins .
We have now found that this can be achieved using oligouronates, i.e. multiply charged hydroxyl group carrying oligomers, in particular one containing two to thirty monomer residues .
Elsewhere in the respiratory tract, in particular in the sinuses, especially the paranasal sinuses, overly viscous mucous can present problems. Oligouronates, can also be used to address these problems.
Thus, viewed from one aspect the invention provides a method of treatment of a human or non-human (e.g. mammalian) subject to combat mucosal hyperviscosity in the respiratory tract, e.g. to treat chronic obstructive pulmonary disease, sinusitis or cystic fibrosis patients, which method comprises application to a mucosal surface in said tract in said subject of an effective amount of a physiologically tolerable oligouronate polyol.
Viewed from a further aspect the invention provides the use of a physiologically tolerable oligouronate for the manufacture of a medicament for use in the treatment of ■mucosal hyperviscosity in the respiratory tract.
The application of the oligouronate may be by any means which delivers it to a mucus secreting, or mucus carrying surface in the patient's respiratory tract, e.g. the paranasal sinuses or more preferably the lungs. Introduction will typically be by inhalation, e.g. of liquid^ droplets (for example an aerosol) or a powder.
The counterions for the oligouronate may be any of the physiologically tolerable ions commonly used for charged drug substances, e.g. sodium, potassium, ammonium, chloride, mesylate, meglumine, etc. Ions which promote alginate gelation, e.g. group 2 metals, however will preferably not be used.
While the oligouronate may be a synthetic material, it is preferably a derivative, having a weight average molecular weight of less than 100000 Da, of a naturally occurring polysaccharide. It is preferably a 3- to 28- mer, in particular a 4- to 25-mer, especially a 6- to 22-mer, in particular an 8- to 15-mer, especially a 10- mer, e.g. having a molecular weight in the range 350 to 6000 Da especially 750 to 4500 Da. It may be a single compound or it may be a mixture of oligouronate compounds, e.g. of a range of degrees of polymerization. Moreover, the monomeric residues in the oligouronate, e.g. the monosaccharide groups, may be the same or different and not all need carry electrically charged groups although it is preferred that the majority (e.g. at least 60%, preferably at least 80% more preferably at least 90%) do. It is preferred that a substantial majority, e.g. at least 80%, more preferably at least 90% of the charged groups have the same polarity. In the oligouronate, the ratio of hydroxyl groups to charged groups is preferably at least 2:1, more especially at least 3:1.
Oligouronates are readily accessible from natural sources since many natural polysaccharides contain charged uronate residues, e.g. residues such as guluronic and galacturonic acid residues.
Polysaccharide to oligosaccharide cleavage to produce oligosuronate useable according to the present invention may be performed using conventional polysaccharide lysis techniques such as enzymatic digestion and acid hydrolysis . Oligouronates may then be separated from the polysaccharide breakdown products chromatographycalIy using an ion exchange resin or by fractionated precipitation or solubilization.
The oligouronates may also be chemically modified, including but not limited to modification to add charged groups (such as carboxylated or carboxymethylated glycans), and oligouronates modified to alter flexibility (e.g. by periodate oxidation)
Suitable polysaccharides are discussed for example in "Handbook of Hydrocolloids" , Ed. Phillips and Williams, CRC, Boca Raton, Florida, USA, 2000. The use of alginates however is especially preferred as these naturally occur as block copolymers of manuronic (M) and guluronic (G) acids and G-block oligomers can readily be produced from alginate source materials . Indeed, in general the oligouronate is preferably an oligoguluronic acid, or less preferably an oligogalacturonic acid.
Where alginates are used as the starting material for preparation of the oligouronate, the guluronic acid content may if desired be increased by epimerization with mannouronan C-5 epimerases from A. vinelandii .
Oligoguluronic acids suitable for use according to the invention may conveniently be produced by acid hydrolysis of alginic acid from Laminaria hyperborea, dissolution at neutral pH, addition of mineral acid to reduce the pH to 3.4 to precipitate the oligoguluronic acid, washing with weak acid, resuspension at neutral pH and freeze drying.
Viewed from a further aspect the invention also provides a pharmaceutical composition, especially an inhalable composition, e.g. a solution, suspension, dispersion or powder, comprising a physiologically tolerable oligouronate together with a physiologically tolerable carrier or excipient, and preferably also a further physiologically tolerable mucosal viscosity reducing agent, e.g. a nucleic acid cleaving enzyme (e.g. a DNAse such as DNase I) , gelsolin, a thiol reducing agent, an acetylcysteine, sodium chloride, an uncharged low molecular weight polysaccharide (e.g. dextran) , arginine (or other nitric oxide precursors or synthesis stimulators), or an anionic polyamino acid (e.g. poly ASP or poly GLU) . The use of a DNase is especially preferred. The oligouronate may be administered typically in doses of 1 to lOOOOmg, especially 10 to lOOOmg for an adult human. The optimum does may readily be determined by routine dosage ranging experiments, optionally following initial investigation of an animal model, e.g. a dog model.
The compositions of the invention may be produced using conventional pharmaceutical carriers and excipients, e.g. solvents (such as water), osmolality modifiers, flavours, pH regulators, etc. They may contain additional active components, for example agents which serve to break down biopolymers not involved in the mucin matrix of the mucus (e.g. DNase, particularly rhDNase) , antibacterial agents, and antiinflammatories. Combination therapy using a such further agent and the oligouronate, administered separately or together is a particularly preferred aspect of the method of the invention. Such further agents may be used in their normal doses or even at lower doses, e.g. 50% of normal dose.
The oligouronates are desirably administered as a spray, preferably an aerosol spray made from an aqueous solution or in the form of powders, e.g. of approximately nanometer to micrometer (e.g. 10 to 50000 nm) mode particle size by volume size.
Viewed from a further aspect the invention provides a spray applicator comprising a reservoir and a droplet generator, said reservoir containing an aqueous solution of a physiologically tolerable oligouronate. Such spray applicators, and indeed the oligouroantes, may be used in the treatment of sinus or nasal blockage or congestion resulting from the common cold or other reasons .
The invention will now be described further with reference to the following non-limiting Examples and the accompanying drawings, in which:
Figures Ia to If are plots of complex modulus over time for a mucin-alginate gel and for the same gel dosed with dextran, polyethylene glycol, DNA, sodium galacturonate oligomer and sodium guluronate oligomer respectively;
Figures 2 and 3 are bar charts showing the complex modulus (G*) and the phase angle of the same gels at the end of gelation as a percentage of the control;
Figure 4 is a bar chart showing the flow stress of the same gels, again as a percentage of the control;
Figures 5a and 5b show the complex modulus G* for treated and untreated sputum samples from CF patients, Figure 5b showing G* as a percentage of control (the untreated sputum) ; Figures 5c to 5f show plots of G* over time;
Figures 6a and 6b show the complex viscosity (η*) for treated and untreated sputum samples, Figure 6b showing η* as a percentage of control; and
Figures 7a and 7b show the phase angle δ for treated and untreated sputum samples . Figure 7b showing δ as a percentage of control.
EXAMPLE 1
The effect of five oligomeric materials on a model mucin-alginate gel were tested: - a) Low molecular weight dextran (6000 Da) b) Low molecular weight PEG (3350 Da) c) Low molecular weight DNA d) Sodium galacturonate oligomers e) Sodium guluronate oligomers (G blocks)
The sodium guluronate oligomer was prepared as described above and had the following characteristics:
FG 0 . 87 , FM 0 . 13 , FGG 0 . 83 , FGM=FMG 0 . 05 , FMM 0 . 08 , FGGM=FMMG 0 . 04 , FMGM 0 . 02 , FGGG 0 . 79 , DP 19 .
Materials
Control gel consisted of 18mg/ml mucin + 0.6mg/ml alginate in 0.05M NaCl
Test gels consisted of 18mg/ml mucin + 0.6mg/ml alginate + 4mg/ml test material in 0.05 M NaCl
Rheological tests
Gelation - immediately after mixing the sample was loaded into the rheometer at 370C. The temperature was cooled to 1O0C (0.5 degree/min) and then held at 1O0C for 18 hours. The behaviour of the sample and gel development was measured continuously.
Frequency sweep - after gelation the temperature of the sample was raised to 370C and the rheological behaviour monitored as a function of frequency.
Stress sweep - at 370C, the behaviour of the gel was monitored as a function of increasing applied stress.
Gelation
The studies demonstrated that sodium guluronate oligomers (G blocks) are able to displace alginate in mucin - alginate interactions as seen by the decrease in the complex modulus of the gel (G*) over time after the initial gelation. For the five test gels and the control gel this is shown in Figures Ia to If respectively.
Of the other oligomeric materials tested only sodium galacturonate oligomers had a similar effect, showing a decrease in the moduli values over time. The other materials (DNA, PEG, dextran) caused a delay in gelation but the gel continued to develop over time as shown by the increase in complex modulus .
The complex modulus and phase angle of the gels at the end of the gelling period is plotted in Figures 2 and 3. The complex modulus is a measure of the total response or strength of the system and the phase angle concerns the balance between liquid like and solid like behaviour with a higher phase angle indicating greater liquid like behaviour. Sodium guluronate oligomers (G blocks) caused the greatest drop in G* and the greatest increase in the phase angle.
Gel behaviour from the frequency sweep
All the gels showed frequency sweep behaviour typical of weak viscoelastic gels .
Flow stress from the stress sweep
A stress sweep was used to determine the stress needed to induce flow in the system. This is plotted in Figure 4 as a % of the stress needed to induce flow in the control gel. This gives an indication of how much the added material has weakened the gel matrix. G blocks (sodium guluronate oligomers) had the most pronounced effect on the flow stress followed by sodium galacturonate oligomers .
EXAMPLE 2
Effect on sputum
Sputum samples were collected from cystic fibrosis patients with a positive diagnosis for Pseudomonas aeruginosa infection. The samples were gently stirred, divided into portions, frozen and stored at -400C.
Pre-testing procedure:
The sputum samples were taken out from the freezer and placed in the fridge (4°C) one hour before testing, stirred on a magnetic stirrer for about 10 min and divided into 0.5 g portions. Testing media was added to all but one sample, the pure sputum sample. The resulting samples were:
A 0.5g sputum (pure)
B 0.5g sputum + 65μl 35OmM NaCl solution (ionic strength of the added guluronate oligomer)
C 0.5g sputum + 75μl 150mg/ml Sodium guluronate oligomers Dpi9
D 0.5g sputum + 75μl 150mg/ml Sodium guluronate oligomers DpIO
The sodium guluronate oligomer Dp 10 (degree of polymerization) had the following characteristics: FG 0.79, PM 0.11, FGG 0.76, FGM=FMG 0.03, FMM 0.07, FMGG=FGGM 0.02, FMGM 0.01, FGGG 0.74, FG(red) 0.10, PG (tot) 0.89, NG>i 37, Dp 10
The mixed samples were then gently stirred for 1 min and subsequently placed into the fridge for 5 min before being transferred to the rheometer for testing.
Rheological testing:
Rheological measurements of the pure and mixed sputum was carried out on plate / cone (40mm/l°) using a Rheologica Stress-Tech general purpose rheometer at 1O0C to minimize the effect of proteolytic enzymes .
The rheological characterisation of the pure sputum and sputum mixed with testing media was performed in four different steps:
Oscillating strain control for 2 min with constant strain 0.03 and frequency at 1 Hz.
Oscillating strain control after pre-shear (1 min at 20 s"1 shear rate) for 60 min with constant strain at 0.03 and frequency at 1 Hz .
Frequency sweep with range from 0.01 - 5 Hz at constant strain 0.03.
Stress sweep with range from 0.02 -20 Pa at 1 Hz.
Figure 5a is bar chart showing the complex modulus (G*) for the sputum samples at the end of testing, after 60 min. Figure 5b is bar chart showing the same sputum samples as in figure 5a, but as percentage of the control (pure sputum) .
Figure 5c to 5f are plots of complex modulus over time for the sputum samples A to D. Figure 6a is bar chart showing the complex viscosity (η*) for the sputum samples at the end of testing, after 60 min. Figure 6b is bar chart showing the same sputum samples as in figure 6a, but as percentage of the control .
Figure 7a is bar chart showing the phase angle (δ) for the sputum samples at the end of testing, after 60 min. Figure 7b is bar chart showing the same sputum samples as in figure 3a, but as percentage of the control.
Addition of guluronate oligomers obviously reduces the mechanical properties of CF sputum ex vivo. Both the complex dynamic modulus as well as the complex dynamic viscosity is considerably reduced, in some cases by as much as a factor of 5. Dp 10 appears to be more effective than the sample with an average Dp of 19. Results obtained from preparing the sputum samples as described also suggest that the CF sputum obtain equilibrium-like mechanical properties faster in the presence of Dp 10 G-blocks than in the presence of other components (G* and η* independent upon time) . The change in the phase angle is, however, not effected to such an extent as G* and η*. This is most important since it clearly shows that the mechanical properties of the mucin network is preserved and hence still able to function as a first line of defence against air-borne pollutants .
EXAMPLE 3 Aerosol
A sterile aerosol spray, administered by the aid of a nebuliser, is made from a liquid containing 3-10% of the sodium salt of a guluronic acid block with a purity of at least 75% guluronate and a degree of polymerisation between 5 and 20, and, if necessary, a surface active compound to stabilise the aerosol droplet size.

Claims

Claims
1. A method of treatment of a human or non-human subject to combat mucosal hyperviscosity in the respiratory tract, which method comprises application to a mucosal surface in said tract in said subject of an effective amount of a physiologically tolerable oligouronate.
2. A method as claimed in claim 1 for the treatment of cystic fibrosis .
3. A method as claimed in either of , claims 1 and 2 for the treatment of sinusitis.
4. A method as claimed in claim 1 for the treatment of chronic obstructive pulmonary diseases.
5. A method as claimed in any one of claims 1 to 4 wherein said oligouronate is administered into the patient's airway.
6. A method as claimed in any one of claims 1 to 5 wherein said oligouronate comprises guluronic acid as a monomer .
7. A method as claimed in any one of claims 1 to 6 wherein said oligouronate is a 4- to 25-mer.
8. The use of a physiologically tolerable oligouronate for the manufacture of a medicament for use in the treatment of mucosal hyperviscosity in the respiratory tract.
9. Use as claimed in claim 8 of an oligouronate as defined in either of claims 6 and 7.
10. Use as claimed in either of claims 8 and 9 for the manufacture of an inhalable medicament for use in the treatment of cystic fibrosis,
11. Use as claimed in any one of claims 8 to 10 for the manufacture of an inhalable medicament for use in the treatment of sinusitis .
12. Use as claimed in either of claims 8 and 9 for the manufacture of an inhalable medicament for use in the treatment of chronic obstructive pulmonary diseases.
13. An inhalable pharmaceutical composition comprising a physiologically tolerable oligouronate together with a physiologically tolerable carrier or excipient.
14. A composition as claimed in claim 13 containing a further physiologically tolerable mucosal viscosity reducing agent.
15. A composition as claimed in either of claims 13 and
14 containing an oligouronate as defined in either of claims 6 and 7.
16. A composition as claimed in any one of claims 13 to
15 containing a DNase.
17. A spray applicator comprising a reservoir and a droplet generator, said reservoir containing an aqueous solution of a physiologically tolerable oligouronate.
PCT/GB2006/003720 2005-10-06 2006-10-06 Use of oligouronates for treating mucus hyperviscosity WO2007039754A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2624568A CA2624568C (en) 2005-10-06 2006-10-06 Oligouronate treatment
JP2008534075A JP5313677B2 (en) 2005-10-06 2006-10-06 Use of oligouronic acid for the treatment of mucosal hyperviscosity
KR1020087010474A KR101144576B1 (en) 2005-10-06 2006-10-06 Use of oligouronate for treating mucus hyperviscosity
AU2006298544A AU2006298544B2 (en) 2005-10-06 2006-10-06 Use of oligouronates for treating mucus hyperviscosity
DK06794671.5T DK1942938T3 (en) 2005-10-06 2006-10-06 Use of oligouronates to treat mucus hyperviscosity
BRPI0616982A BRPI0616982B8 (en) 2005-10-06 2006-10-06 use of oligouronate, inhalable pharmaceutical composition and spray applicator
ES06794671T ES2390974T3 (en) 2005-10-06 2006-10-06 Use of oliguronates to treat hyperviscosity of mucus
EP06794671A EP1942938B1 (en) 2005-10-06 2006-10-06 Use of oligouronates for treating mucus hyperviscosity
US12/089,529 US8754063B2 (en) 2005-10-06 2006-10-06 Use of oligouronates for treating mucus hyperviscosity
CN2006800460615A CN101325973B (en) 2005-10-06 2006-10-06 Use of oligouronates for treating mucus hyperviscosity
EA200801033A EA015436B1 (en) 2005-10-06 2006-10-06 Use of oligouronates for treating mucus hyperviscosity
HK09104636.3A HK1125855A1 (en) 2005-10-06 2009-05-21 Use of oligouronates for treating mucus hyperviscosity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0520375.7 2005-10-06
GB0520375A GB2430881B (en) 2005-10-06 2005-10-06 Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity

Publications (1)

Publication Number Publication Date
WO2007039754A1 true WO2007039754A1 (en) 2007-04-12

Family

ID=35429950

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2006/003732 WO2007039760A2 (en) 2005-10-06 2006-10-06 Use of oligouronates for treating mucus hyperviscosity
PCT/GB2006/003720 WO2007039754A1 (en) 2005-10-06 2006-10-06 Use of oligouronates for treating mucus hyperviscosity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003732 WO2007039760A2 (en) 2005-10-06 2006-10-06 Use of oligouronates for treating mucus hyperviscosity

Country Status (15)

Country Link
US (2) US8754063B2 (en)
EP (4) EP1954315A2 (en)
JP (1) JP5313677B2 (en)
KR (1) KR101144576B1 (en)
CN (1) CN101325973B (en)
AU (1) AU2006298544B2 (en)
BR (1) BRPI0616982B8 (en)
CA (1) CA2624568C (en)
DK (3) DK1942938T3 (en)
EA (1) EA015436B1 (en)
ES (3) ES2390974T3 (en)
GB (1) GB2430881B (en)
HK (1) HK1125855A1 (en)
PL (1) PL3403657T3 (en)
WO (2) WO2007039760A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008125828A2 (en) * 2007-04-12 2008-10-23 Ntnu Technology Transfer As Oligo-guluronate and galacturonate compositions
WO2010139959A2 (en) 2009-06-03 2010-12-09 Algipharma Ipr As Alginate oligomers for the inhibition of microbial adherence to surfaces
WO2010139957A1 (en) 2009-06-03 2010-12-09 Algipharma Ipr As Alginate oligomers for use in overcoming multidrug resistance in bacteria
WO2010139958A1 (en) 2009-06-03 2010-12-09 Algipharma Ipr As Anti-microbial alginate oligomers
WO2013038197A1 (en) 2011-09-15 2013-03-21 Algipharma As Use of alginate oligomers to enhance the effects of antifungal agents
US8529890B2 (en) 2009-03-23 2013-09-10 Ntnu Technology Transfer As Composition for the administration of polymeric drugs
US8673878B2 (en) 2005-10-06 2014-03-18 Ntnu Technology Transfer As Mucosal treatment
US8680072B2 (en) 2007-11-27 2014-03-25 Algipharma As Use of alginate oligomers in combating biofilms
US8987215B2 (en) 2009-03-23 2015-03-24 Ntnu Technology Transfer As Composition for use in gene therapy
WO2015128495A1 (en) * 2014-02-28 2015-09-03 Algipharma As Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
WO2016151051A1 (en) * 2015-03-23 2016-09-29 Algipharma As Use of alginate oligomers and cftr modulators in the treatment of conditions associated with cftr dysfunction
WO2020025617A1 (en) 2018-07-31 2020-02-06 Algipharma As Method for the qualitative and quantitative detection of alginate oligomers in body fluids
WO2020254427A1 (en) 2019-06-17 2020-12-24 Algipharma As Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure
US11413306B2 (en) 2015-10-06 2022-08-16 Algipharma As Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract
US11712448B2 (en) 2013-12-20 2023-08-01 Algipharma As Use of alginate oligomers as blood anticoagulants
US11992553B2 (en) 2014-08-29 2024-05-28 Algipharma As Inhalable powder formulations of alginate oligomers

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
JP2017501221A (en) * 2013-12-23 2017-01-12 ノルウェージャン ユニバーシティ オブ サイエンス アンド テクノロジー（エヌティーエヌユー） Use of oligouronates in cancer treatment
FR3024358B1 (en) * 2014-08-01 2017-11-10 Soc De Courtage Et De Diffusion Codif Int COSMETIC COMPOSITIONS AND FOOD COMPONENTS NEURO-PROTECTIVE COMPRISING OLIGOALGINATE HAVING A POLYMERIZATION DEGREE OF 10 TO PREVENT AGING OF THE SKIN.
CN115005447B (en) * 2022-06-16 2024-02-06 青岛海关技术中心 Application of oligoguluronic acid in preparation of anti-fatigue product

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1042379A (en) 1956-12-20 1966-09-14 Alexander Farkas Improvements in or relating to polyuronides
WO1988009794A1 (en) 1987-06-02 1988-12-15 Walsh William E Cyclopolyglycuronic acid composition and its use
EP0324720A1 (en) * 1988-01-14 1989-07-19 Warner-Lambert Company Saccharide inhibition of dental plaque
EP1714660A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7576M (en) * 1968-03-27 1970-01-05
HU172831B (en) * 1976-03-31 1978-12-28 Egyt Gyogyszervegyeszeti Gyar Process for producing complex compounds of oligo- and polygalacturonic acids with essential metal ions
JPS6176413A (en) 1984-09-21 1986-04-18 Junzo Sunamoto Production of liposome encapsulated with water-absorbing high polymer
DD268865A1 (en) * 1987-01-16 1989-06-14 Adw Ddr PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATORY
JP2641472B2 (en) 1988-01-30 1997-08-13 日本レダリー株式会社 Infectious disease treatment
US5459054A (en) 1989-12-05 1995-10-17 Neocrin Company Cells encapsulated in alginate containing a high content of a- l- guluronic acid
WO1991007951A1 (en) 1989-12-05 1991-06-13 Trancel Corporation Homologous guluronic acid alginate coating composition for in-vivo application and implantation and method of using same
WO1991011205A1 (en) 1990-01-23 1991-08-08 Trancel Corporation Mannuronic acid containing alginate wound healing composition and method
US5166137A (en) * 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
US5952308A (en) * 1991-07-29 1999-09-14 Pola Chemical Industries Inc. Mineral absorption promoting agent
US5460957A (en) * 1992-04-28 1995-10-24 Maruha Corporation Calcium alginate oligosaccharide and method for producing the same from potassium or sodium alginate
HU213872B (en) 1993-09-08 1997-11-28 Mta Koezponti Kemiai Kutato In Oligo- and polygalacturonate mixed complex, pharmaceutical and food compositions containing them, further process for preparing these compounds
DE4330773A1 (en) * 1993-09-10 1995-03-16 Laevosan Gmbh & Co Kg Blocking the attachment of germs to human cells
JP2828391B2 (en) * 1993-10-29 1998-11-25 東燃株式会社 Liposomes with oligosaccharides on the surface
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
DE69637625D1 (en) * 1995-10-19 2008-09-18 Bio Origyn Llc METHODS AND COMPOSITIONS THAT IMPROVE THE SURVIVAL AND FUNCTION OF GERMAN CELLS AND EMBRYOS
JP3512553B2 (en) 1996-01-30 2004-03-29 ポーラ化成工業株式会社 Constipation inhibitor and composition containing it
FR2747045B1 (en) * 1996-04-05 1998-06-26 Hooreman Michel NEW MEDICINE OPTIMIZING THE VISCOSITY OF MUCUSES AND IMPROVING THE FUNCTIONING OF THE INTESTIN
NO305441B1 (en) 1996-07-12 1999-05-31 Norsk Hydro As Use of G-block polysaccharides
CA2266622C (en) 1996-09-27 2006-08-15 Hyal Pharmaceutical Corporation Hyaluronic drug delivery system
NO305033B1 (en) * 1997-05-09 1999-03-22 Algipharma As Process for the preparation of uric acid blocks from alginate
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
KR100219918B1 (en) 1997-07-03 1999-09-01 김윤 Composition for colon specific drug delivery
JP3932679B2 (en) 1998-07-21 2007-06-20 セイコーエプソン株式会社 Production method of polyguluronic acid
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
EP1212047A2 (en) * 1999-08-26 2002-06-12 The Governors Of The University Of Alberta Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
KR100501584B1 (en) * 2000-02-03 2005-07-18 (주)케이비피 Process for preparing low molecular polymannuronate, a novel use thereof as controller of serum lipids, and functional foods and health-aid foods comprising the same
DE10006989A1 (en) * 2000-02-16 2001-08-23 Nutricia Nv Pharmaceutical or dietetic preparation for preventing cellular adhesion of pathogens, e.g. in treatment of infections, comprising carbohydrate having double bond-containing terminal uronic acid unit
RU2274442C2 (en) 2000-03-07 2006-04-20 Раш-Презбитериан-Ст. Лук'С Медикал Сентер Compositions and methods for entrapping and inactivation of pathogenic microorganisms and spermatozoids
WO2001072278A2 (en) 2000-03-30 2001-10-04 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
DE10019076A1 (en) * 2000-04-06 2001-10-18 Lang Christine Use of polygalacturonides as food additives
JP2002338493A (en) 2000-10-23 2002-11-27 Genaera Corp Mucin synthesis inhibitor
DE10057976B4 (en) 2000-11-22 2005-02-03 Südzucker AG Mannheim/Ochsenfurt Process for the preparation of pectin hydrolysis products
US6440314B1 (en) * 2001-01-03 2002-08-27 Vulcan Chemical Technologies, Inc. Method for destroying chlorite in solution
ITMI20010347A1 (en) 2001-02-21 2002-08-21 Grisotech S A IMMUNOGLOBULIN AND POLYSACCHARID COMPLEXES FOR ORAL ABSORPTION ETRANS-MUCOSAL
US6610331B1 (en) 2002-05-30 2003-08-26 Scott M. Sweazy Fertility kit
JP2005145885A (en) 2003-11-14 2005-06-09 Japan Science & Technology Agency Immunologic mechanism activator comprising alginic acid oligomer
PT1740154E (en) 2004-03-12 2009-09-11 Biodel Inc Insulin compositions with improved absorption
JP4764426B2 (en) * 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド Cationic lipids and methods of use
JP2006028041A (en) 2004-07-13 2006-02-02 Ltt Bio-Pharma Co Ltd Nucleic acid-containing nano particle
US7621036B2 (en) 2005-06-21 2009-11-24 Cardiomems, Inc. Method of manufacturing implantable wireless sensor for in vivo pressure measurement
EP1745705A1 (en) 2005-07-20 2007-01-24 N.V. Nutricia Process for preparing uronic acid oligosaccharides by extrusion
GB2430881B (en) 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
MX2008004962A (en) 2005-10-21 2009-03-02 Living Cell Products Pty Ltd Encapsulation system.
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
US20110130444A1 (en) 2007-05-04 2011-06-02 Stefan Moisyadi Methods and compositions for targeted delivery of gene therapeutic vectors
CA2724408A1 (en) 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1042379A (en) 1956-12-20 1966-09-14 Alexander Farkas Improvements in or relating to polyuronides
WO1988009794A1 (en) 1987-06-02 1988-12-15 Walsh William E Cyclopolyglycuronic acid composition and its use
EP0324720A1 (en) * 1988-01-14 1989-07-19 Warner-Lambert Company Saccharide inhibition of dental plaque
EP1714660A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754063B2 (en) 2005-10-06 2014-06-17 NTNU Technology Transfers AS Use of oligouronates for treating mucus hyperviscosity
US8673878B2 (en) 2005-10-06 2014-03-18 Ntnu Technology Transfer As Mucosal treatment
EA018776B1 (en) * 2007-04-12 2013-10-30 ЭнТиЭнЮ ТЕКНОЛОДЖИ ТРАНСФЕР АС Pharmaceutical composition comprising oligo-guluronate or galacturonate, methods of treatment using same, use thereof and spray applicator comprising same
US8841279B2 (en) 2007-04-12 2014-09-23 Norwegian University Of Science And Technology Oligo-guluronate and galacturonate compositions
EP2500025A1 (en) 2007-04-12 2012-09-19 NTNU Technology Transfer AS Oligo-guluronate and galacturonate compositions
WO2008125828A2 (en) * 2007-04-12 2008-10-23 Ntnu Technology Transfer As Oligo-guluronate and galacturonate compositions
AU2008237710B2 (en) * 2007-04-12 2014-02-06 Ntnu Technology Transfer As Oligo-guluronate and galacturonate compositions
WO2008125828A3 (en) * 2007-04-12 2009-06-04 Ntnu Technology Transfer As Oligo-guluronate and galacturonate compositions
US9877983B2 (en) 2007-11-27 2018-01-30 Algipharma As Use of alginate oligomers in combating biofilms
US10624920B2 (en) 2007-11-27 2020-04-21 Algipharma As Use of alginate oligomers in combating biofilms
US8680072B2 (en) 2007-11-27 2014-03-25 Algipharma As Use of alginate oligomers in combating biofilms
US8987215B2 (en) 2009-03-23 2015-03-24 Ntnu Technology Transfer As Composition for use in gene therapy
US8529890B2 (en) 2009-03-23 2013-09-10 Ntnu Technology Transfer As Composition for the administration of polymeric drugs
US8815831B2 (en) 2009-06-03 2014-08-26 Algipharma As Treatment of Acinetobacter with alginate oligomers and antibiotics
WO2010139958A1 (en) 2009-06-03 2010-12-09 Algipharma Ipr As Anti-microbial alginate oligomers
WO2010139956A1 (en) 2009-06-03 2010-12-09 Algipharma Ipr As Treatment of acinetobacter with alginate oligomers and antibiotics
US9018158B2 (en) 2009-06-03 2015-04-28 Algipharma As Alginate oligomers for use in overcoming multidrug resistance in bacteria
US9801901B2 (en) 2009-06-03 2017-10-31 Algipharma As Alginate oligomers for use in overcoming multidrug resistance in bacteria
WO2010139957A1 (en) 2009-06-03 2010-12-09 Algipharma Ipr As Alginate oligomers for use in overcoming multidrug resistance in bacteria
WO2010139959A2 (en) 2009-06-03 2010-12-09 Algipharma Ipr As Alginate oligomers for the inhibition of microbial adherence to surfaces
WO2013038197A1 (en) 2011-09-15 2013-03-21 Algipharma As Use of alginate oligomers to enhance the effects of antifungal agents
US11712448B2 (en) 2013-12-20 2023-08-01 Algipharma As Use of alginate oligomers as blood anticoagulants
WO2015128495A1 (en) * 2014-02-28 2015-09-03 Algipharma As Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
US11992553B2 (en) 2014-08-29 2024-05-28 Algipharma As Inhalable powder formulations of alginate oligomers
AU2016236172B2 (en) * 2015-03-23 2021-07-01 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfunction
US10751363B2 (en) 2015-03-23 2020-08-25 Algipharma As Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction
WO2016151051A1 (en) * 2015-03-23 2016-09-29 Algipharma As Use of alginate oligomers and cftr modulators in the treatment of conditions associated with cftr dysfunction
US11413306B2 (en) 2015-10-06 2022-08-16 Algipharma As Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract
US11385174B2 (en) 2018-07-31 2022-07-12 Algipharma As Method for the qualitative and quantitative detection of alginate oligomers in body fluids
WO2020025617A1 (en) 2018-07-31 2020-02-06 Algipharma As Method for the qualitative and quantitative detection of alginate oligomers in body fluids
WO2020254427A1 (en) 2019-06-17 2020-12-24 Algipharma As Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure

Also Published As

Publication number Publication date
EP1942938B1 (en) 2012-07-04
GB2430881B (en) 2010-10-13
PL3403657T3 (en) 2022-03-21
US20090010914A1 (en) 2009-01-08
GB0520375D0 (en) 2005-11-16
DK1942938T3 (en) 2012-09-17
US20090156549A1 (en) 2009-06-18
AU2006298544B2 (en) 2012-07-05
DK3403657T3 (en) 2022-02-28
JP2009511455A (en) 2009-03-19
BRPI0616982A2 (en) 2011-07-05
EP1942938A1 (en) 2008-07-16
DK2311497T3 (en) 2018-10-22
EA200801033A1 (en) 2008-10-30
WO2007039760A2 (en) 2007-04-12
BRPI0616982B1 (en) 2020-05-05
AU2006298544A1 (en) 2007-04-12
KR20080080491A (en) 2008-09-04
ES2907875T3 (en) 2022-04-26
HK1125855A1 (en) 2009-08-21
CN101325973A (en) 2008-12-17
EP3403657B1 (en) 2021-12-08
ES2390974T3 (en) 2012-11-20
BRPI0616982B8 (en) 2021-05-25
US8754063B2 (en) 2014-06-17
JP5313677B2 (en) 2013-10-09
EP3403657A1 (en) 2018-11-21
US8673878B2 (en) 2014-03-18
KR101144576B1 (en) 2012-05-09
GB2430881A (en) 2007-04-11
CA2624568A1 (en) 2007-04-12
WO2007039760A3 (en) 2007-08-09
CA2624568C (en) 2014-04-08
ES2688971T3 (en) 2018-11-07
EP1954315A2 (en) 2008-08-13
EP2311497A1 (en) 2011-04-20
EP2311497B1 (en) 2018-07-11
EA015436B1 (en) 2011-08-30
CN101325973B (en) 2013-02-13

Similar Documents

Publication Publication Date Title
US8754063B2 (en) Use of oligouronates for treating mucus hyperviscosity
US10729786B2 (en) Mucus penetrating gene carriers
KR101336459B1 (en) Oligo-guluronate and galacturonate compositions
EP1407776B1 (en) A pharmaceutical colloidal preparation comprising hyaluronic acid biopolymers useful in the treatment of respiratory diseases
CA2540699A1 (en) Polysaccharides for pulmonary delivery of active agents
MX2008004472A (en) Use of oligouronates for treating mucus hyperviscosity
CN117693352A (en) Glutathione C4 against airway diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680046061.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2624568

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004472

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008534075

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087010474

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 3741/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006794671

Country of ref document: EP

Ref document number: 2006298544

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200801033

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2006298544

Country of ref document: AU

Date of ref document: 20061006

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006298544

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006794671

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12089529

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0616982

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080407